eflornithine has been researched along with Glioblastoma in 8 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade gliomas, the benefit for glioblastoma patients remains unproven." | 9.09 | Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. ( Bruner, JM; Chang, SM; Choucair, A; Flynn, PJ; Gleason, MJ; Hess, KR; Jaeckle, KA; Kyritsis, AP; Levin, VA; Prados, MD; Uhm, JH, 2000) |
| "This study compared the antitumor activity of oral eflornithine with that of oral eflornithine combined with intravenous mitoguazone in the treatment of patients with recurrent or progressive glioblastoma multiforme as well as nonglioblastoma anaplastic gliomas." | 9.07 | Treatment of recurrent gliomas with eflornithine. ( Gleason, MJ; Ictech, S; Levin, VA; Malec, M; Prados, MD; Yung, WK, 1992) |
| " For these reasons, the anti-glioblastoma drug temozolomide was tested in vitro for activity against bloodstream forms of T." | 7.85 | Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine. ( Rushworth, SA; Steverding, D, 2017) |
| "Although the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade gliomas, the benefit for glioblastoma patients remains unproven." | 5.09 | Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. ( Bruner, JM; Chang, SM; Choucair, A; Flynn, PJ; Gleason, MJ; Hess, KR; Jaeckle, KA; Kyritsis, AP; Levin, VA; Prados, MD; Uhm, JH, 2000) |
| "This study compared the antitumor activity of oral eflornithine with that of oral eflornithine combined with intravenous mitoguazone in the treatment of patients with recurrent or progressive glioblastoma multiforme as well as nonglioblastoma anaplastic gliomas." | 5.07 | Treatment of recurrent gliomas with eflornithine. ( Gleason, MJ; Ictech, S; Levin, VA; Malec, M; Prados, MD; Yung, WK, 1992) |
| " For these reasons, the anti-glioblastoma drug temozolomide was tested in vitro for activity against bloodstream forms of T." | 3.85 | Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine. ( Rushworth, SA; Steverding, D, 2017) |
| "Glioblastoma is characterized by the robust infiltration of immunosuppressive tumor-associated myeloid cells (TAMCs)." | 1.62 | Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma. ( Burga, R; Burns, M; Castro, B; Chandel, NS; Cordero, A; Gao, P; Han, Y; Horbinski, CM; Hou, D; Lee-Chang, C; Lesniak, MS; Lopez-Rosas, A; Miska, J; Rashidi, A; Reshetnyak, YK; Sampat, S; Stoolman, JS; Xiao, T; Zhang, P, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Miska, J | 1 |
| Rashidi, A | 1 |
| Lee-Chang, C | 1 |
| Gao, P | 1 |
| Lopez-Rosas, A | 1 |
| Zhang, P | 1 |
| Burga, R | 1 |
| Castro, B | 1 |
| Xiao, T | 1 |
| Han, Y | 1 |
| Hou, D | 1 |
| Sampat, S | 1 |
| Cordero, A | 1 |
| Stoolman, JS | 1 |
| Horbinski, CM | 1 |
| Burns, M | 1 |
| Reshetnyak, YK | 1 |
| Chandel, NS | 1 |
| Lesniak, MS | 1 |
| Steverding, D | 1 |
| Rushworth, SA | 1 |
| Levin, VA | 4 |
| Uhm, JH | 1 |
| Jaeckle, KA | 2 |
| Choucair, A | 1 |
| Flynn, PJ | 1 |
| Prados, MD | 4 |
| Bruner, JM | 1 |
| Chang, SM | 2 |
| Kyritsis, AP | 2 |
| Gleason, MJ | 2 |
| Hess, KR | 2 |
| Wara, WM | 1 |
| Sneed, PK | 1 |
| McDermott, M | 1 |
| Rabbitt, J | 1 |
| Page, M | 1 |
| Malec, M | 2 |
| Davis, RL | 1 |
| Gutin, PH | 1 |
| Lamborn, K | 1 |
| Wilson, CB | 1 |
| Phillips, TL | 1 |
| Larson, DA | 1 |
| Wong, ET | 1 |
| Yung, WK | 2 |
| Ictech, S | 1 |
| Prados, M | 1 |
| Rodriguez, L | 1 |
| Chamberlain, M | 1 |
| Silver, P | 1 |
| Levin, V | 1 |
1 review available for eflornithine and Glioblastoma
| Article | Year |
|---|---|
Chemotherapy of primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Brain Stem; Child; Efl | 1985 |
4 trials available for eflornithine and Glioblastoma
| Article | Year |
|---|---|
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; | 2000 |
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Disease-Free Surviva | 2001 |
Response and progression in recurrent malignant glioma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine | 1999 |
Treatment of recurrent gliomas with eflornithine.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Child, Preschool; Eflornithine; Female; Glioblastom | 1992 |
3 other studies available for eflornithine and Glioblastoma
| Article | Year |
|---|---|
Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Survival; Eflornithine; Glioblastoma; Hydrogen-Ion Concent | 2021 |
Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Eflornit | 2017 |
Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1989 |